WuXi AppTec (HK: 2359) and WuXi Biologics (HK: 2269) rose 4% and 3.5%, respectively, in Hong Kong trade, extending gains into ...

[ET Net News Agency, 12 June 2025] ASCENTAGE-B (06855) rose 0.9% to HK$60. It hits an intra-day high of HK$60.3, hitting a historical high, and an intra-day low of HK$58.95. The total shares traded ...

Big pharmaceutical companies are seeing Chinese biotech as the disruptors. Read more at straitstimes.com. Read more at ...

Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an unspecified up-front payment, research costs ...

Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert Bourla, that landed in Pfizer’s cancer ...

Pfizer CEO Albert Bourla has pulled back the curtain on his $1.25 billion bet on a PD-1xVEGF bispecific, revealing that his ...

Pfizer offers a high 7.4% dividend yield and trades at low valuation multiples. Click here to read more about PFE stock and ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

[ET Net News Agency, 9 June 2025] EVEREST MED (01952) rose 10.3% to HK$52.55. It hits an intra-day high of HK$52.55, hitting an 1-month high, breaking above the 50-D SMA of HK$48.025, and an intra-day ...

US drug companies are increasingly licensing experimental medicines invented by Chinese firms. The recent deals could be ...

BMY teams with BioNTech on BNT327, a dual-target cancer therapy, as legacy drugs face mounting generic pressure ...